Patient considerations in the management of ulcerative colitis – role of vedolizumab

Abstract

Megha Kothari, Prashant Mudireddy, Arun SwaminathDivision of Gastroenterology and Hepatology, Lenox Hill Hospital-NSLIJ, New York, NY, USAAbstract: Ulcerative colitis (UC) is a subtype of inflammatory bowel disease which causes inflammation of the large intestine and affects approximately 7.6–24.6 per 100,000 persons. The therapeutic goal for UC patients is inducing remission, maintaining remission, and ideally, obtaining mucosal healing. Vedolizumab, approved by the US Food and Drug Administration in May 2014 for the treatment of moderate-to-severe UC and Crohn’s disease, is a newly developed anti-integrin therapy. This review focuses on the preclinical development of vedolizumab and data from early trials, and details the results of the landmark trails that led to its approval in the USA with a specific focus on the management of UC. Additionally, data on safety and the current UC management protocols are also discussed. Keywords: inflammation, mucosal healing, remission, immunomodulator drugs, infliximab, ulcerative colitis